Sansure Biotech Inc
Sansure Biotech Inc. researches and develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. It offers nucleic acid and multiple nucleic acid diagnostic kits for coronavirus, CoV-2, influenza virus, and respiratory syncytial virus; DNA fluorescence and nucleic acid diagnostic kits for respiratory tract infections, HPV infections, and reproductive tr… Read more
Sansure Biotech Inc - Asset Resilience Ratio
Sansure Biotech Inc (688289) has an Asset Resilience Ratio of 1.50% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Sansure Biotech Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Sansure Biotech Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥141.90 Million | 1.5% |
| Total Liquid Assets | CN¥141.90 Million | 1.50% |
Asset Resilience Insights
- Limited Liquidity: Sansure Biotech Inc maintains only 1.50% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Sansure Biotech Inc Industry Peers by Asset Resilience Ratio
Compare Sansure Biotech Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Beijing Centergate Technologies Holding Co Ltd
SHE:000931 |
Medical Instruments & Supplies | 0.06% |
|
Blue Sail Medical Co Ltd
SHE:002382 |
Medical Instruments & Supplies | 5.12% |
|
Andon Health Co Ltd
SHE:002432 |
Medical Instruments & Supplies | 35.75% |
|
Allmed Medical Products Co Ltd Class A
SHE:002950 |
Medical Instruments & Supplies | 3.78% |
|
Inix Technologies Holdings Bhd
KLSE:0094 |
Medical Instruments & Supplies | 0.06% |
|
Focus Point Holdings Bhd
KLSE:0157 |
Medical Instruments & Supplies | 2.30% |
|
Careplus Group Bhd
KLSE:0163 |
Medical Instruments & Supplies | 4.91% |
|
LKL International Bhd
KLSE:0182 |
Medical Instruments & Supplies | 0.38% |
Annual Asset Resilience Ratio for Sansure Biotech Inc (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Sansure Biotech Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 1.62% | CN¥139.67 Million | CN¥8.60 Billion | -4.86pp |
| 2023-12-31 | 6.49% | CN¥548.28 Million | CN¥8.45 Billion | -20.23pp |
| 2022-12-31 | 26.72% | CN¥2.45 Billion | CN¥9.17 Billion | -2.14pp |
| 2021-12-31 | 28.86% | CN¥2.05 Billion | CN¥7.09 Billion | -0.49pp |
| 2020-12-31 | 29.36% | CN¥1.60 Billion | CN¥5.45 Billion | +19.03pp |
| 2019-12-31 | 10.32% | CN¥66.33 Million | CN¥642.47 Million | -- |